Prevalence of Protein-energy Wasting and Obesity Among Danish Dialysis Patients

December 15, 2014 updated by: Mette Koefoed, Zealand University Hospital
The purpose of this study is to determine the prevalence of protein-energy wasting and obesity among Danish dialysis patients.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Undernutrition among dialysis patients is associated with increased morbidity and mortality.

Conversely, in hemodialysis (HD) patients a high BMI in the range of obesity has long been known protective against death and cardiovascular disease, a phenomenon called reverse epidemiology. Hence, what is good for the background population might differ from what is good for HD patients.

In peritoneal dialysis (PD) patients this association is less clear. The majority of studies find reverse epidemiology, however some studies find no survival advantage of obesity or even indicate a higher risk of death in obese patients. Some authors claim that reverse epidemiology is a misconception and that although in the short run a high BMI is protective a follow up period of more than five years show increased mortality. Considering this Mutsert et al. claim that HD patients have the same mortality risk patterns associated with BMI as the general population.

Moreover, it has been shown that the protective effect of a high BMI or weight gain is limited to those with normal or high muscle mass. Patients with high BMI and malnutrition have a high risk of death. Concordantly, recent studies show that abdominal obesity is associated with mortality among dialysis patients .

The prevalence of under-nutrition, often known as protein energy wasting (PEW), among dialysis patients varies from 31% to 51% and the prevalence of obesity varies from 10-56% presumably depending on the diagnostic criteria and the method used. These inconsistent results make comparison of the prevalence of undernutrition and obesity among dialysis populations somewhat problematic.

In order to standardize the diagnosis of PEW in dialysis patients International Society of Renal Nutrition and Metabolism (ISRNM) suggest diagnostic criteria. As goes for obesity, there are no standardized methods for diagnosing this among dialysis patients. However, reviews recommend using multiple different methods concurrently including BMI, fat percentage (FM%), and measures of abdominal fat.

Data on the nutritional status among dialysis patients in Northern Europe are primary derived from a single research center (Karolinska institute, Sweden) and there is no recent published data on the prevalence of PEW among dialysis patients. A single study examines the prevalence of obesity.

Few studies have compared the nutritional status of HD and PD patients. Hardly any studies examine the prevalence of undernutrition and obesity in the same population.

Knowing the nutritional status of a dialysis population and identifying already malnourished patients, can contribute the quality of the care provided.

Hence, the aim of this study is, for the first time in Northern Europe to assess the prevalence of both PEW and obesity in the same population using the ISRNM criteria as well as different obesity markers. Additionally, we compare the nutritional status of HD and PD patients.

Design The study was designed as a cross-sectional study, investigating the nutritional status of hemodialysis (HD) patients and peritoneal dialysis (PD) patients attending the dialysis centre at Roskilde Hospital, Denmark in February to June 2014.

Subjects All PD, HD and home-HD patients (n = 105) were invited to participate. Patients who refused to participate were invited to complete a partial nutritional examination. The participating eligible patients all gave their written consent. Patient data (age, gender, dialysis vintage, primary kidney disease and co morbid conditions were taken from the patient records. The local ethical committee approved the study protocol.

Anthropometric measurements Anthropometric measurements were performed immediately after a dialysis session (HD) as recommended by the HEMO study or after the monthly ambulatory control (PD, home-HD). All measurements were done on the non-access side of the body for HD-patients and on the right side for PD-patients. Skin folds (SF) were measured with a Harpenden caliper and all circumferences were done using a non-stretchable fiberglass insertion tape (seca 201). All measurements were made by to well-trained research assistants.

Height (h) and bodyweight (BW) was measured in light clothing using standard instrument in the dialysis centre. For PD the weighing was preferably done with empty abdominal cavity, for those (n=8) who refused to empty the abdominal cavity the bodyweight was calculated as BW with dialysate minus the volume of dialysate that was last drained into the abdomen. For patients with lower leg amputations (n=2) 6.2% of total bodyweight per amputated leg was added to the measured weight

Fat mass was assessed according to a formula described by Durnin and Womersley based on four skinfold thicknesses (biceps, triceps, subscapular and suprailiac). Mid-arm circumference (MAC) was measured midway between acromion and olecranon. All measurements were done in duplicate. If the two measurements were more than four mm apart, two additional measurements were done and the mean of all four was calculated. This approach is recommended by "CLINICAL PRACTICE GUIDELINES For Nutrition of Chronic Renal Failure". Triceps skinfold (TSF) and MAC was used to calculate corrected mid-arm muscle area (cMAMA) as described by Heymsfield SB et al.

Waist circumference (WC) was measured as recommended by WHO. Patients unable to stand had their waist and hip circumference measurement done in supine position. The waist and hip measurements were skipped if empty abdominal cavity was not feasible for PD patients. All measurements were done in duplicate if the difference between the two measurements exceeded 1 cm, two more measurements were done, and the mean of all four calculated.

Lean body mass index (LBMI) and fat mass index (FMI) was calculated as lean body mass (LBM)/h2 and fat mass (FM)/h2 respectively as described by Kyle et al.

Blood sampling and biochemical measurements For assessment of s-transferrin and albumin blood samples were from all patients was analyzed at the laboratory at Roskilde Sygehus, Denmark. Kt/V was measured as described by F.A.Gotch(Gotch 1998). For HD-patients normalized protein catabolic rate (nPCR) was determined by measuring the interdialytic rise of blood urea nitrogen after a midweek dialysis session. For patients with residual urine output > 300ml/day urinary nitrogen excretion was also taken into account. To account for day-to-day variations we calculated a mean of three nPCR measurements, which were made over a 2 months period after the anthropometric measurements, we only made one urine sample. For PD-patients nPCR was measured using the Bergstroms' formula. Only one nPCR measurement was done for PD patients

Study Type

Observational

Enrollment (Actual)

105

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients receiving regular dialysis therapy at Roskilde Hospital, Denmark in February to June 2014.

Description

Inclusion Criteria:

  • all dialysis patients receiving dialysis therapy at Roskilde Hospital, Denmark

Exclusion Criteria:

  • < 3 months dialysis
  • fever
  • antibiotic treatment
  • major surgery within 2 weeks
  • disseminated cancer
  • age below 18
  • psychosis
  • pregnancy
  • physical or mental disability where participation was not feasible,
  • language barriers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
PD patients
Patients receiving peritoneal dialysis. No intervention
no intervention
HD patients
Patients receiving hemodialysis. No intervention
no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Undernutrition
Time Frame: 3 months

Classification of undernutrition Undernutrition was assessed 3 different methods: 1) WHO cut-off of BMI < 18,5kg/m2, 2) the criteria for protein-energy wasting (PEW) defined by the International Society of Renal Nutrition and Metabolism (ISRNM) and 3) our own criteria for PEW based on fat mass index (FMI) and a lean body mass index (LBMI).

According to ISRNM, PEW is present if at least one abnormal measure is recorded is in at least three of the four categories. We measured the four markers: albumin, BMI, corrected mid-arm muscle area (cMAMA) and normalized protein catabolic rate (nPCR) (a measure of daily protein intake (DPI)).

Classification of under nutrition BMI < 18,5kg/m2 FMI<10th percentile and LBMI <10th percentile

PEW 3 of 4:

  • Serum albumin < 38g/L
  • BMI < 23
  • cMAMA reduction >10% in relation to 50th percentile of reference population
  • Unintentional low DPI < 0,8g/kg/d
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Obesity
Time Frame: 3 months

As recommended by Zoccali et al obesity was assessed using different criteria based on either BMI, fat percentage (FM%), waist circumference (WC) and waist hip ratio (WHR). Cut off values for BMI, WC and WHR were based on WHO criteria. Cut off values for FM% were based on earlier published recommendations. In addition we calculated FMI, and defined obesity as a FMI >90th percentile of the reference population.

Classification of obesity BMI>30kg/m2 FMI > 90th percentile Fat percentage > 25% (men) or 35% (women) WC > 102cm (men) or 88cm (women) WHR > 0,90 (men) or 0,85 (women)

3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Peter Marckmann, Zealand University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2014

Primary Completion (Actual)

June 1, 2014

Study Completion (Actual)

June 1, 2014

Study Registration Dates

First Submitted

December 10, 2014

First Submitted That Met QC Criteria

December 15, 2014

First Posted (Estimate)

December 19, 2014

Study Record Updates

Last Update Posted (Estimate)

December 19, 2014

Last Update Submitted That Met QC Criteria

December 15, 2014

Last Verified

December 1, 2014

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on No intervention

3
Subscribe